Jiangsu Hengrui Medicine (600276.SS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $49.55B | Exchange | SHH |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | CN | CEO | Piao Yang Sun |
| IPO Date | 2000-10-18 | CAGR | 18.02% |
| Employees | 20,602 | Website | www.hrs.com.cn |
| Div. Yield | 0.54% | Payout Ratio | 16% |
| Buy Back Yield | 0.44% | Total Yield | 0.98% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $45.63B | P/E | 42.22 | Forward P/E | 30.88 | PEG | 3.24 |
| P/S | 7.09 | P/B | 3.76 | P/CF | 20.75 | P/FCF | 27.03 |
| Sales | $4.81B | Sales 1Y | 11.55% | Sales 3Y | 52.96% | Sales 5Y | 11.76% |
| EPS | $0.18 | EPS 1Y | 14.81% | EPS 3Y | 103.28% | EPS 5Y | 22.77% |
| Sales QoQ | -3.56% | EPS QoQ | 20.69% | Sales QoQ Avg | 3.91% | EPS QoQ Avg | 12.26% |
| Gross Margin | 86.24% | Operating Margin | 27.54% | Profit Margin | 24.93% | ROCE | 13.66% |
| ROA | 11% | ROE | 13% | Altman Z Score | 31.66 | Piotroski Score | 5 |
| Current Ratio | 9.23 | Quick Ratio | 8.72 | Cash Ratio | 7.19 | Op. CF Ratio | 0.14 |
| Debt/Equity | 0 | Debt/Assets | 0 | Lt Debt/Equity | 0 | Lt Debt/Cap. | — |
| Intrst Cov. | 2315.17 | Inventory Turnover | 1.55 | Asset Turnover | 0.46 | Receivables Turnover | 5 |
| Enterprise Value | $45.63B | P/E Ratio | 42.22 |
| Forward P/E | 30.88 | PEG Ratio | 3.24 |
| P/S Ratio | 7.09 | P/B Ratio | 3.76 |
| P/CF Ratio | 20.75 | P/FCF Ratio | 27.03 |
| EPS | $0.18 | EPS Growth 1Y | 14.81% |
| EPS Growth 3Y | 103.28% | EPS Growth 5Y | 22.77% |
| Revenue Growth 1Y | 11.55% | Gross Margin | 0.86% |
| Operating Margin | 0.28% | Profit Margin | 0.25% |
| ROE | 0.13% | ROA | 0.11% |
| ROCE | 0.14% | Current Ratio | 9.23 |
| Quick Ratio | 8.72 | Cash Ratio | 7.19 |
| Debt/Equity | 0 | Interest Coverage | 2315.17 |
| Altman Z Score | 31.66 | Piotroski Score | 5 |
Jiangsu Hengrui Medicine (600276.SS) valuation & financials
Jiangsu Hengrui Medicine (600276.SS) has a market capitalization of 49.55B CNY and trades at a price-to-earnings ratio of 42.2. It operates in the Healthcare sector (Drug Manufacturers - General).
Jiangsu Hengrui Medicine's revenue grew +11.5% over the last year.
Jiangsu Hengrui Medicine's next earnings report is scheduled for August 19, 2026; analysts estimate EPS of 0.06 CNY. Check the earnings calendar to see all companies reporting this week.
Jiangsu Hengrui Medicine (600276.SS) — frequently asked questions
When does Jiangsu Hengrui Medicine (600276.SS) report earnings next?
Jiangsu Hengrui Medicine is expected to report earnings on August 19, 2026. Analysts estimate EPS of 0.06 CNY.
What is Jiangsu Hengrui Medicine's market cap?
Jiangsu Hengrui Medicine (600276.SS) has a market capitalization of 49.55B CNY.
What is 600276.SS's P/E ratio?
Jiangsu Hengrui Medicine trades at a price-to-earnings ratio of 42.2, with trailing twelve-month EPS of 0.18 CNY.
How fast is Jiangsu Hengrui Medicine growing?
Jiangsu Hengrui Medicine's revenue grew +11.5% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)